Thu, Jul 24, 2014, 1:05 PM EDT - U.S. Markets close in 2 hrs 55 mins

Recent

% | $
Click the to save as a favorite.

Cytori Therapeutics, Inc. Message Board

rothco619 112 posts  |  Last Activity: 18 hours ago Member since: Aug 29, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Athena trial

    by maccruises Apr 25, 2014 10:13 AM
    rothco619 rothco619 Apr 25, 2014 10:56 AM Flag

    Mac, Wishing you a speedy recovery. I pray you received the real treatment and are rewarded with a healthier and better quality of life.

  • Reply to

    down 6.5% with a miserable 200k shares traded

    by brettstar48 Apr 25, 2014 2:18 PM
    rothco619 rothco619 Apr 25, 2014 4:33 PM Flag

    totaljim is a basher and a short. he does not hold any shares of cytori and has not been around for quite some time. he shows up when things are going poorly to rub salt in the wounds.jim posts the same thing whenever he does post which is that cellution machine is a centrifuge and worht nothing,so take his posts from the source.While he is correct about what he says about the management team as well as performance to date,but tell us something we don't know.

  • Reply to

    Someone bot around 50,000 share

    by meh8767 Apr 25, 2014 4:53 PM
    rothco619 rothco619 Apr 25, 2014 7:34 PM Flag

    hedge when do May warrants expire ? when do sept warrants expire and do you recall the price they are set at ? I'm drawing a blank

  • Ten times your wildest dreams!
    Was an assessment delivered by Lloyd Dean, Chairman of the Cytori Board of Directors concerning the future stockprice of Cytori, during the annual meeting of shareholders in August 2011. Made at a time that most shareholders were moaning about the lack of execution of Cytori management and exactly this guy- certainly not the least influencial and one of the most respected CEO´s in the healthcare space in the US (Catholic Healthcare West- in charge of 12 Billion of Assets and said to have personal "access" to President Obama)- wanted us to believe that Cytori had an excellent management team, for which as of to date- early March 2012 -due to lacking indications in respect of accomplishments, no substance to that statement has been provided or can be shown.

    What Dean (picture) surely has been confronted with in his tenure with Cytori, which has covered a time span of roughly 20 months now, is the incredible potential of ADRCs in general, which becomes clear and evident when one studies the available scientific literature and evidence.

    Nonetheless the inability of Cytori management to convince BIG PHARMA partner candidates sofar in jointly developing this incredible potential is very disheartening, but as always the belief is still there that one find day the blind squirrel finally finds his nut and Dean´s assessment of the quality of Cytori management is provided with some "colour".

    Untill that time however- in view of scarce (financial) resources for a Company that employs 120 highly paid staff, primarily consisting of directors and vice-presidents, obviously the focus can only lie on issues that are to some extent controllable- i.e. continue to develop what has matured to the largest degree, which happens to be the soft tissue, cardiac and wound healing applications.

  • Reply to

    Ten Times your wildest dreams

    by rothco619 Apr 26, 2014 3:12 PM
    rothco619 rothco619 Apr 26, 2014 10:48 PM Flag

    i did not write this it was written by an excerpt from an article written 2 years ago. glad your pleased with how well things are going. was never interested in selling at three and not mad that i didn't ,

  • Reply to

    The good news

    by myownhedgefund Apr 28, 2014 11:29 AM
    rothco619 rothco619 Apr 28, 2014 12:48 PM Flag

    I have been re-evaluating my position on Cytori. As there has been much discussion about warrants I would like to post below which came from transcript of 2012 annual shareholders meeting . Considering our current state of affairs with May warrants set to expire and Sept only 5 months away the below concerns me.
    Lewis Bosher: My name is Lewis Bosher and I’m a private investor. I address this to Mark Saad. The comments have been made about cash and adding $20-30 million to that cash, with a burn rate calculated in there, would take you to the breakeven level. There have also been comments about the stock price moving up and warrants and stock options converting over to provide another $40 million. So we’re talking about somewhere between 5 quarters and maybe 9 quarters until you reach the breakeven. My question really is, are you counting on the warrants being converted to cash just to breakeven?
    Mark Saad: No, we’re not. The number that I mentioned was the aggregate from where we are today. If we look, and I appreciate the question because its an important clarification, that when we look at what are the available sources of that cash, there are either new transactions with corporate or financial parties or existing transactions, like the exercise of those warrants and options.
    So what was defined as an aggregate need can be met by any number of things, though the important point being that if you have $70+ million available of the already existing warrants and options, that is one potential source. That can be typically discounted especially when they have average lives of several years. So we focus in on what’s expiring within the next one to two years as more of a near term, realistic, when can you see those realistically exercise. So within that one to two years zone is about $40 million worth.
    And no, that is not factored into my estimate of the $20-$30 million at all. And then the additional, other sources when we look at in the aggregate, we believe we have

  • Reply to

    The good news

    by myownhedgefund Apr 28, 2014 11:29 AM
    rothco619 rothco619 Apr 28, 2014 12:53 PM Flag

    well north of $100 million of available things we’ve got working on. And how do we measure what we have, what are the nearest term, looking at our needs, what are the nearest term needs, while wearing bifocals and looking ahead and trying to maximize the value creation.
    Clearly, we have many times over the need addressable by the existing things that are in our field of activity. And then trying to maximize the quality of how that money comes in, either through strategic or warrants or if we do a financing deal, if we do something with a party that we think is, we think has aligned interests with what we’re doing and bringing in the right amounts to not do things that are negative at overhangs to the company. So that’s the field of what we’re doing in parallel on all those fronts on a daily basis and I hope that’s clear.

  • Reply to

    Someone bot around 50,000 share

    by meh8767 Apr 25, 2014 4:53 PM
    rothco619 rothco619 Apr 29, 2014 3:36 PM Flag

    This might have something to do with it. can't be good.
    forbesDOTcom/sites/larryhusten/2014/04/28/stem-cell-therapy-to-fix-the-heart-a-house-of-cards-about-to-fall/

  • Reply to

    Sellers worked to close this flat

    by myownhedgefund Apr 30, 2014 4:24 PM
    rothco619 rothco619 May 1, 2014 10:23 AM Flag

    Going to reply to myself with another scenario. You stated trading days which takes you to the 13th a day after Q! earnings reported so perhaps they are good and pps will pop and then warrants would be exercised. Crazy game this Wall Street casino.

  • Reply to

    Sellers worked to close this flat

    by myownhedgefund Apr 30, 2014 4:24 PM
    rothco619 rothco619 May 1, 2014 10:27 AM Flag

    8 trading days takes you to the 13th which is a day after Q! earnings so and I'm grasping for straws here if earnings are good and pps pops perhaps warrants would be execised and Cytori raises some much needed capital. I don't hold any warrants just stock but hope those that do, don't have them expire worthless.
    What a crazy game this Wall Street Casino is.

  • Reply to

    Cytori vs Merrimack Pharmaceuticals

    by maccruises May 1, 2014 9:40 AM
    rothco619 rothco619 May 1, 2014 10:29 AM Flag

    Completely agree with your point Mac, I think Hedge has missed your point.

  • Reply to

    Cytori vs Merrimack Pharmaceuticals

    by maccruises May 1, 2014 9:40 AM
    rothco619 rothco619 May 1, 2014 11:58 AM Flag

    Hedge the fact that mac has has participated in the Athena trial gives him more credibility then anyone else on this board when it comes to value of life extension. to compare heart disease to cancer and that extending the life of one patient vs another is just ignorant. nothing personal.

  • Reply to

    Athena trial

    by maccruises May 1, 2014 3:30 PM
    rothco619 rothco619 May 1, 2014 9:13 PM Flag

    glad your doing well. hope you received treatment this time and not placebo. it's great that you will be treated if you did. appreciate your updates,thank you

  • Reply to

    Athena trial

    by maccruises May 1, 2014 3:30 PM
    rothco619 rothco619 May 2, 2014 3:49 PM Flag

    I just don't get the CYTORI decision making process and that they had to think about giving patients that received placebo treatment for free at later date. It just goes along with all the other poor decsions they make. They would rather be foolish and have difficulty fully enrolling trial and delay even more what is moving at a snails pace as it is. Par for the course. Better late then never I guess . We so need a competent CEO. Imagine how much further along we would be if we had one . They just continue to operate by trial and error,it sad just sad.

  • Reply to

    Athena and Plastic Surgeon

    by maccruises May 2, 2014 12:29 PM
    rothco619 rothco619 May 2, 2014 3:53 PM Flag

    Mac, I notice that your position on Cytori is a strong sell. That seems odd, since you are receiving treatment that may save your life. Would you please explain why you have a strong cell opinion.

  • Reply to

    Athena trial

    by maccruises May 1, 2014 3:30 PM
    rothco619 rothco619 May 2, 2014 4:08 PM Flag

    you got that right for sure cyt. it's pathetic go down one road, bump into a wall, go down another road, change direction, start again, going after breast construction, not going after breast reconstruction, aplications good for plastic surgery no wait it isn't. no wonder we sit here at $2.30 down from $8.50. Operating on the blind squirrel management theory is ineffective, expensive, and why nobody believes a dam thing this
    management team tells us. Hope they gain some credibility on BARDA announcement which is supposed to come in 2nd quarter.

  • Reply to

    Athena and Plastic Surgeon

    by maccruises May 2, 2014 12:29 PM
    rothco619 rothco619 May 2, 2014 4:10 PM Flag

    yes i see now, thanks for pointing that out it was very strange,

  • rothco619 rothco619 May 4, 2014 5:13 PM Flag

    charlie a very similar article came out about 3 years ago raising same type of concerns more focus on leakage damage. We thought our ship had come in as Cytori had been telling us what focus they had on this. Nothing materialized, no reimbursement I think was the problem. It just seems we have all this promise and then just when we think this is , and then it is snatched away. Hope BARDA breaks the trend and our foutunes turn.

  • Reply to

    BARDA IPR Date Set

    by wall_street_titan May 5, 2014 8:08 AM
    rothco619 rothco619 May 5, 2014 10:28 AM Flag

    Good to see communication with shareholders for the first time I can remember. This is surely the most important meeting Cytori will have , and is a make or break IMHO.

  • Reply to

    BARDA IPR Date Set

    by wall_street_titan May 5, 2014 8:08 AM
    rothco619 rothco619 May 5, 2014 11:07 AM Flag

    They had to complete the meetings as it was a pre-requisite to set this review,according to what mangement explained to us during the last call.

CYTX
2.15-0.05(-2.27%)1:04 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.